There is general agreement that levodopa is the most effective therapeutic agent presently available for the treatment of Parkinsonism. The general principles underlying its use in clinical practice, its effectiveness, its side-effects and its limitations are now well documented in an extensive and rapidly growing literature. How- ever, nearly all the data reported to date concern the use of levodopa in patients with Parkinson's disease. To our knowledge, only two reports (Calne, Stern, Lawrence, Sharkey, and Armitage, 1969; Krasner and Cornelius, 1970 )-plus several 'letters to the editor' (Sacks and Kohl, 1970a, b; Sacks, Kohl, Schwartz, and Messelhoff, 1970c; Sacks, Messelhoff, and Schwartz, 1970d) -dealing specifically with the use of levodopa in postencephalitic Parkinsonism have been published. It is difficult to draw any firm conclusions from the small number of patients de- scribed, and the relatively short periods over which they were observed, regarding the indications, contraindications, and efficacy of 
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levodopa in this distinctive and specific aetiological type of Parkinsonism. Moreover, little has been noted about the effects of levodopa on important sequelae of encephalitis lethargica other than Parkinsonism such as oculogyric crises, ocular and bulbar palsies, tics, dystonic postures and movements, or the sleep and behavioural disorders commonly encountered in postencephalitic patients. Accordingly, we think it worthwhile to report our experience with long-term levodopa therapy in a large series of patients with a well-documented diagnosis of postencephalitic Parkinsonism.
METHODS
Thirty-three patients considered to have postencephalitic Parkinsonism were included among a large number of patients admitted to a clinical investigation of levodopa in the treatment of Parkinsonism conducted at the Columbia-Presbyterian Medical Center. All were personally interviewed and examined. After a careful review of all the available clinical data, they were classified as 'definitely', 'probably', or 'possibly' postencephalitic according to criteria defined in a previous study Roger C. Duvoisin, Joao Lobo-Antunes, and Melvint D. Yahr of postencephalitic Parkinsonism (Duvoisin and Yahr, 1965) . (Sixteen of the patients had been among the subjects of that study.) Two patients whose clinical picture was complicated by brain tumour and one with a slowly progressive atypical Parkinsonism syndrome who was considered to be only 'possibly' postencephalitic were omitted from the present analysis.
There remained 30 patients who were considered to be either definitely or probably postencephalitic (Table 1) . Twenty-six were classified as 'definitely' postencephalitic. Twenty-three of these had both a The severity of the Parkinsonism was assessed weekly or more frequently during the initial periods of treatment and at each follow-up visit. The degree of disability was evaluated according to a five stage scale previously described by Hoehn and Yahr (1967) Rigidity, tremor, speech, facial expression, seborrhoea, salivation, bradykinesia, the manner of rising from a chair, posture, gait, postural stability, finger dexterity, and the performance of rapid alternating movements with hands and feet were evaluated in a standard manner and each item was rated on a carefully defined five point scale. The sum of the ratings constituted a score which was considered an index of the overall severity of Parkinsonism. The difference between treatment and pretreatment scores was divided by the latter and the result multiplied by 100 to calculate the percentage of improvement in each case. Special attention was directed to the incidence and duration of the oculogyric crises.
Complete physical examination and screening tests were carried out in all patients in order to exclude cardiovascular, renal, hepatic, or haematological disorders. Blood counts, urinalyses, and routine blood chemical analyses were performed at each visit in all patients. Electrocardiograms were performed before commencing levodopa and repeated at varying intervals.
Our method of treatment was to continue each patient's previous medication and add levodopa in small initial doses, using tablets or capsules of 250 mg and 500 mg. The dosage and schedule were modified according to the responses observed in each patient with a high degree of individualization in order to achieve the best compromise between benefits and side effects. The average daily dose of levodopa was 2-8 g. An effort was made to discontinue previous anti-Parkinsonism drugs after a response to levodopa was observed but results were nearly always better with a combination of two or more types of drugs and only two patients remained on levodopa alone. Eleven patients received two or three anti-Parkinsonism agents, mainly of the anticholinergic type, in addition to levodopa. Amantadine HCI was also employed in four patients.
RESULTS
Twenty-two of the thirty patients were still on levodopa therapy at the time of writing. One patient died during the 10th month of treatment. Levodopa was discontinued in seven patients for reasons to be detailed below after periods of time ranging from one to 11 months. Four were discontinued after less than three months of treatment. Three were discontinued after longer periods; one after four months, another after eight months, and the third after 11 months. We feel that these three patients were treated for a sufficient period of time to permit a fair assessment of the benefits as well as the side-effects of levodopa therapy. Accordingly, we calculated the therapeutic improvements obtained in a total of 26 patients who remained on levodopa therapy for a minimum of four to a maximum of 38 months (mean 16-8 months). The results are shown in Table 2 . Oculogyric crises were present in nine patients. The approximate incidence of oculogyric crises before and after treatment is detailed in Table 3 . compromise between benefit and side-effects was attained which still gave these patients a significant if less than ideal therapeutic response.
As noted above, levodopa therapy was ultimately discontinued in seven patients. In one patient it was withdrawn because of a cardiac arrhythmia which was considered to be lifethreatening. In the remainder it was withdrawn because the side-effects (involuntary movements in two, malaise and vertigo in another, and behavioural disturbances in three) persisted to an unacceptable degree, despite reduction in the dosage to levels yielding little or no therapeutic benefit.
The patient who died during the 10th month of treatment apparently expired in his sleep. He was found dead in bed. No necropsy was performed and the cause of death is unknown. However, because of a previous history of myocardial infarction, a cardiac death may reasonably be suspected.
The side-reactions encountered are summarized in Table 4 . Nausea and vomiting were reported by nine patients but did not represent a major difficulty, subsiding spontaneously in time or with adequate adjustment of the medication. Irregularity of the cardiac rhythm was noticed in three patients. Involuntary movements occurred in 19 patients, involving chiefly the facial musculature. In three patients, the movements consisted of bizarre respiratory patterns with irregular hyperpnoea. One patient complained of 'grunting'. The three patients who had choreiform involuntary movements before beginning levodopa treatment experienced an increase in these movements even on very small doses of levodopa. In one patient with a previous orofacial dyskinesia the movements were intolerably severe even at doses of levodopa yielding relatively little improvement and precluded increasing the dosage to an effective level. This patient was consequently unable to benefit from levodopa. However, the other two patients with previous dyskinetic phenomena obtained significant benefit from doses of levodopa which did not increase their dyskinesia to unacceptable proportions. Postural hypotension was observed in only one patient and was mild and transient in duration.
The psychic side-effects encountered warrant a more detailed account. They occurred in nine patients but in only three was levodopa discontinued. These three patients became actively psychotic, with compulsive behaviour, confusion, and severe agitation. One had received levodopa with a-methyldopa hydrazine (MK-486-a dopadecarboxylase inhibitor) and, although a dramatic improvement of the neurological status with a 950 % reduction of the pretrial score was obtained in four days, a severe behavioural disorder rendered the patient unmanageable. The same symptoms recurred on treatment with levodopa alone at a very modest dose (1-5 g daily).
Six patients with behavioural disturbances were able to continue on levodopa treatment at a lower dosage and still derive significant benefit. In one of these patients bizarre, socially inappropriate, behaviour which had occurred many years before seemed to be reactivated. He would enter neighbouring homes without knock-ing and uninvited, enter automobiles stopped temporarily at traffic lights and accost passers-by on the street to offer them a haircut (he had once been a barber). she had a coarse tremor of the left hand and loss of associated movements of the left upper extremity when walking. The neurological examination was otherwise unremarkable. Two years later tremor of the right hand was noted. Subsequent progression of her illness was very gradual. In 1956 she began to develop a thoracic kyphosis. Her gait subsequently deteriorated and her voice became soft and increasingly difficult to understand. By 1957 she walked with short steps with loss of associated movements and had moderate rigidity and cogwheeling in all extremities and a coarse tremor of the hands. Rapid alternating and succession movements were performed poorly. Ocular convergence was impaired, and a hyperactive glabellar reflex was present. Trihexyphenidyl, 8 mg daily, apparently gave some symptomatic improvement but by 1959 her equilibrium was severely impaired and she suffered frequent falls. Two years later she had occasional episodes of angina pectoris. Signs of congestive heart failure were noted.
She fell with increasing frequency, suffering a Colles's fracture of the right wrist, and several rib fractures and scalp lacerations. In 1965 she began to require increasing help in her activities of daily living and three years later had to be placed in a nursing home.
In November 1968 she was started on a trial of levodopa treatment. At that time the vital signs were normal. There was a soft precordial systolic murmur and mild ankle oedema. A severe dorsal kyphoscoliosis was present with rotation of the head to the right, the chin pressed against the right shoulder. There was a severe rigidity of the paraspinal muscles and extremities, more marked on the left. A minimal tremor of the fingers and tongue was present. The gait was short stepped, with severe festination, and she tended to fall spontaneously. Arising from a chair was difficult and sometimes impossible without assistance. There was a moderate facial masking. The voice was very soft and the speech barely intelligible. Pretrial investigations were normal except for the presence in the electroencephalogram (EEG) of intermittent bitemporal medium to high voltage slow and sharp waves and anterolateral depression of T waves in the electrocardiogram (ECG). Psychomotor testing revealed minimal memory loss and severe deficit on perceptual motor tasks. Previous medications were continued (trihexyphenidyl, 4 mg; diphenhydramine, 75 mg; and benztropine, 2 mg per day) and levodopa was started at a daily dosage of 0 75 g and progressively increased. On 5 g daily she began to have mild nocturnal confusion. Trihexyphenidyl and benztropine were discontinued with improvement of the mental symptoms. However, two days later she developed a supraventricular arrhythmia and levo-dopa was withheld for several days until the ECG reverted to its pre-trial status. However, her signs of Parkinsonism which had shown significant improvement, again became markedly exacerbated. Levo (Cote, Yahr, Duvoisin, Wolf, and Marksbery, 1970 Laboratory investigations were remarkable only for a very low concentration of cerebrospinal fluid homovanillic acid of 7 ng/ml. Trihexyphenidyl was continued and a trial of levodopa was begun at a dose of 05 g daily. The dosage was gradually increased to a daily total of 6 g over a period of one month. This dosage was well tolerated in hospital and significant improvement was apparent; only two oculogyric crises had occurred during this period. Further improvement gradually accrued over the following two months so that a very appreciable overall improvement was realized. The patient became independent in his daily living activities; he attended to his personal needs with minimal supervision, was able to perform minor chores and was able to resume some social activities. Drooling completely ceased. Posture became almost normal and speech was improved. For a brief period there Respontse ofpatients with postencephalitic Parkinsonism to levodopa was a sudden increase in the frequency of oculogyric crises which occurred almost daily and several times on some days. Because the increase was thought possibly to be due to levodopa; the dosage was reduced to 4 g daily. There was then some recrudescence of signs of Parkinsonism. The frequency of oculogyric crises declined and they remained infrequent thereafter, despite increases in the dosage of levodopa again to 6 g daily. However, after a month the dosage was again reduced because of the subsequent development of unusual behaviour which was very distressing to the patient's family. He exhibited numerous compulsions, the most striking of which was a frequent compulsion to polish and count the tiles on the bathroom wall. While shaving or brushing his teeth, the patient would seem to become fascinated with the tiles and would for long periods, sometimes an hour or more, continue to polish them with a wash cloth and count them. Similarly, while watching television he would become interested in the window drape and try endlessly to adjust the pleats. He became angry and resentful when his wife or son would try to stop these activities and on several occasions struck at them belligerently. He exhibited poor judgement, impulsiveness, and socially inappropriate behaviour. He promptly tried to sell to a neighbour a new sports jacket he had received as a gift. He tried to renew his automobile driver's licence and became abusive when his family objected. He telephoned old friends in the middle of the night to invite them to try to organize a party.
Various adjustments in the dosage were attempted but when the dosage was lowered below 5 g the resulting increase in severity of his Parkinsonism rendered him more of an invalid, while increases above 5-25 g per day resulted in excessive compulsive and impulsive behaviour. The best compromise seemed to be about 5 g per day. Oculogyric crises remained markedly decreased throughout a 21 year period in both severity and frequency. There were occasional transient tendencies to look up to the left but frank oculogyric crises were absent for periods lasting up to two to three months and they were quite mild, subsiding in 10 to 15 minutes.
COMMENT The compulsive behaviour exhibited by this patient is among the characteristic sequelae of encephalitis lethargica and was observed in a large proportion of its survivors. It was clearly increased by levodopa and consequently denied this patient the nearly complete reversal of the Parkinsonism that he might otherwise have enjoyed. Nevertheless, with careful adjustment of the dosage schedule of levodopa a compromise was found which produced some annoying behavioural aberrations but at the same time gave a very appreciable improvement of his Parkinsonism. A considerable period of time was required to achieve this satisfactory result.
The transient increase in oculogyric crises observed after three months of treatment in this patient was probably not related to levodopa, since oculogyria remained very mild and infrequent thereafter for a long follow up period of 24 years. DISCUSSION Calne, Sharkey, and Armitage (1969) first reported the results of levodopa treatment in postencephalitic Parkinsonism. They administered maximum tolerated doses of levodopa to a group of 20 patients so disabled that institutional care had been necessary for many years. After six weeks of therapy, seven were substantially improved and three moderately so, while five patients had no useful response. The drug was discontinued in five patients because of sideeffects. The authors concluded that levodopa had a 'useful role' in the management of postencephalitic patients. However, in a subsequent communication dealing with the same patient population, Hunter, Stern, and Sharkey (1970) reported their impression that postencephalitic patients tolerate levodopa poorly, and stated that 'only a minority gain useful and enduring benefit'. Other authors (Krasner and Cornelius, 1970; Sacks et al., 1970a, b, c, and d) also found that postencephalitic patients had limited tolerance for levodopa. They drew attention particularly to the incidence of psychic disturbances, the occurrence of severe 'respiratory crises', and the reactivation of oculogyric crises.
Our experiences contradict these relatively negative assessments of levodopa. Over twothirds of our 30 patients obtained significant improvement over a prolonged period of observation and in most of these the benefits were very substantial. These Although the oculogyric crises were not completely abolished except perhaps in one case, we noted a marked reduction of frequency and severity in six of nine patients and thus we cannot confirm the assertion of Sacks et al. (1970b) that severe reactivation of the oculogyria must be regarded as one of the most distressing sideeffects of levodopa in these patients. The favourable effect of levodopa on oculogyria is consistent with older reports of the efficacy of amphetamine in controlling this phenomenon in postencephalitic patients (Solomon, Mitchell, and Prinzmetal, 1937) . Many of the actions of amphetamine may be due to an enhancement of dopaminergic neurones (Carlsson, 1970) , giving it a certain parallelism with the effects of levodopa which are ascribable to the dopamine to which it is transformed.
We did not observe any aggravation of the socalled 'respiratory crises', but in some patients abnormal respiratory patterns were seen as part of the choreiform syndrome induced by levodopa. These were controlled by a reduction of the dose. Our observations agree with those of Calne et al. (1969) that involuntary movements present before levodopa treatment are made worse.
Among the more striking minor symptoms of postencephalitic Parkinsonism drooling stands out as one which may be markedly improved by levodopa, even in patients in whom large doses of anticholinergic drugs failed to yield a significant benefit. This observation confirms our impression in agreement with Parkinson (1817) that drooling in Parkinsonism is due to failure to direct the saliva posteriorly to the fauces-that is, drooling reflects a motor defect rather than sialorrhoea. The greater improvement of motor function yielded by levodopa than by previous anti-Parkinsonism remedies accounts for its more remarkable effect on this distressing symptom.
Postural hypotension was encountered in only one patient. We may speculate that the involvement of the peripheral nervous system in Parkinson's disease, suggested by the presence of Lewy bodies in sympathetic ganglia (Jager and Bethlem, 1960) , is not present in postencephalitic Parkinsonism, and that postencephalitic patients Responise ofpatients with postenicephalitic Parkinsonism to levodopa are consequently less prone to suffer changes in blood pressure regulation.
The very severe depletion of striatal dopamine found in a patient (case D) , who came to necropsy, more severe than that found in our studies of patients with Parkinson's disease, is in agreement with the earlier observations of Hornykiewicz (1966) . The very low concentration of homovanillic acid in the cerebrospinal fluid of our case 1 presumably reflects this severe dopamine depletion. These findings are consistent with the more severe degeneration of the substantia nigra seen in postencephalitic Parkinsonism (Greenfield and Bosanquet, 1953 
